Please login to the form below

gantenerumab

This page shows the latest gantenerumab news and features for those working in and with pharma, biotech and healthcare.

Roche starts new late-stage trials of Alzheimer’s candidate

Despite yet another failure for another amyloid-targeting drug for Alzheimer’s disease this week, Roche is pressing ahead with two large, phase III trials of its gantenerumab candidate. ... to gantenerumab as a potential new therapy for Alzheimer’s

Latest news

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

s crenezumab and Roche/Chugai’s gantenerumab.
Glimmer of hope for amyloid drugs in Alzheimer's?

Roche also had updated results from a previously-reported trial of its gantenerumab candidate that failed to show a benefit on cognition.
Biogen Idec claims first with Alzheimer's candidate

That view took a knock last December however when Roche announced it was halting a phase III trial of its gantenerumab candidate in prodromal Alzheimer's after an independent panel concluded
AB Science on track for phase III data in Alzheimer's this year

of patients, with a host of failed projects including most recently Roche's gantenerumab.
Double trial disappointment for Roche

The Swiss pharma company will discontinue a phase III programme investigating its anti-amyloid medicine gantenerumab in people in the early stages of Alzheimer's after an analysis of interim data. ... Roche has not given up on gantenerumab completely,

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest from PMHub

Alzheimer’s disease: reviewing the immediate treatment horizon

Crenezumab, gantenerumab, and solanezumab are all involved in additional prospective longitudinal investigations – the Alzheimer’ s Prevention Initiative (Phase 2), the Dominantly Inherited Alzheimer Network study (Phase 2/3), and the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Associate Scientific Director: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Training Manager - Surrey: Competitive Salary &Bonus

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Director, Healthcare Advertising Agency: Salary TBC

Healthcare PR Director: £100, 000 – £120, 000 benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Graduate Scientific Editor: DOE

Account Manager: Negotiable

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Manager- 4 days per week or full-time: Salary TBC

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Healthcare PR Senior Account Manager: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Medical Writer - Creative and Scientific Projects: DOE

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Subscribe to our email news alerts

PMHub

Add my company

W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....